Skip to main content

The director of GAIN visits CiMUS and highlights the good health of the Galician R&D&I ecosystem

  • An international delegation from six countries participating in the Galicia Biobusiness Tour learns about the innovation and research capabilities of the regional biotechnology sector.

An international delegation from six countries participating in the Galicia Biobusiness Tour, promoted by the Galician Innovation Agency (GAIN), visited the USC CiMUS to learn about the potential of the Galician R&D&I ecosystem. The director of GAIN, Carmen Cotelo, encouraged the representatives of the biotechnology sector of this scientific delegation from Italy, Belgium, Portugal, Canada, Japan and the United Kingdom, to take advantage of the occasion to create links that will bear fruit in joint research, dissemination and talent attraction projects.

Cotelo highlighted the research and innovation capabilities of the Galician R&D&I ecosystem, with the example of the Public Foundation for Genomic Medicine and the Innopharma Platform of the University of Santiago, which they had the opportunity to visit in situ. The director of GAIN also highlighted the relevance in the scientific field of figures such as Mabel Loza and Ángel Carracedo, hosts of the visit.


Innopharma, a reference platform in Europe

In this regard, the Regional Ministry of Education, Science, Universities and Vocational Training, through Gain, supported with 5 million euros, from European REACT-EU funds within the Feder Galicia 2014-2020 operational programme, the acquisition and updating of scientific-technological equipment and the recruitment of staff for the Innopharma drug discovery platform, led by USC researchers Mabel Loza and Ángel Carracedo.

This platform is recognised as one of the eight High Capacity Platforms of the European Research Infrastructure Consortium (ERIC IU-Openscreen) and has one of the most important chemolibraries in Spain and Europe.

Xunta de Galicia also supports the activity of the Fundación Pública de Medicina Xenómica through a contract-programme that provides funding for the structural costs of the biomedical research foundation.